Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DGKζ siRNA
- Development stage
- Preclinical
- Lead developer
- Shanghai University of Medicine & Health Science
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
DGKζ siRNA is a small interfering RNA (siRNA) designed to silence the expression of diacylglycerol kinase zeta (DGKζ), a type IV lipid kinase. DGKζ plays a critical role in lipid metabolism by phosphorylating diacylglycerol (DAG) into phosphatidic acid (PA), thereby modulating signaling pathways involved in cell growth and survival. In human glioblastoma (GBM), DGKζ is significantly overexpressed compared to precancerous tissues and is regulated by miR-34a. Treatment with DGKζ siRNA has been shown to inhibit GBM cell proliferation, arrest the cell cycle, promote apoptosis, and reduce tumorigenicity in both in vitro and in vivo models. This suggests that DGKζ is a viable therapeutic target for the treatment of glioblastoma and potentially other cancers like colorectal cancer.
- Other names
- siRNA targeting DGKζDGK-zeta siRNAdiacylglycerol kinase zeta siRNA
02
Targets
DGKZ (Diacylglycerol kinase zeta)Innate immune double-stranded RNA sensors
Beyond the preview
Go deeper on DGKζ siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DGKζ siRNA.